Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Volume 39, Issue 6, 2014, Pages 1399-1408.
psychopharmacology schizophrenia addiction disorders depression anxiety
Pharmacological treatments for depression have insufficient efficacy in 30-40% of patients and fail to reverse cognitive deficits. Erythropoietin (EPO) has neurotrophic actions and aids neurocognitive function. The aim of this exploratory study was to determine whether recombinant human EPO improves mood and memory in treatment-resistant ...More
Full Text (Upload PDF)